Bristol's Yervoy Bursts Out Of The Gate
This article was originally published in The Pink Sheet Daily
Executive Summary
The first-in-class immunotherapy for metastatic melanoma generated $95 million in its first full quarter on the market, exceeding management's expectations.
You may also be interested in...
Bristol/Pfizer's Apixaban: Third To Market But Best-In-Class?
Top-line results from the Phase III ARISTOTLE trial show the novel anticoagulant was superior to warfarin on safety and efficacy - a pleasant surprise for investors.
Bristol Tries Out New Selling Strategy With Yervoy Launch
Bristol-Myers Squibb is using a "new customer model" that takes a holistic approach to supporting Yervoy (ipilimumab), CEO Lamberto Andreotti told analysts on the company's first-quarter earnings call on April 28.
Bristol Basks In Broad Ipilimumab Label, Sets High Price
Labeling does not specify line of therapy, so the melanoma drug could see use beyond very late-stage refractory patient population studied in pivotal trial.